Publications by authors named "Guoying Tai"

Claim this Profile
N
No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches.
Dung Nguyen, Xiusheng Miao, Kunal Taskar, Mindy Magee, Pete Gorycki, Guoying Tai

Pharmacol Res Perspect· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero-Test bile string.
Guoying Tai, Fangming Xia, Cathy Chen, Adrian Pereira, Jill Pirhalla

Pharmacol Res Perspect· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development.
David E Coutant, David W Boulton, Upendra P Dahal, Antoine Deslandes, Christine Grimaldi, Guoying Tai

Clin Pharmacol Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague.
Dung Nguyen, Jafar Sadik Shaik, Guoying Tai, Courtney Tiffany, Caroline Perry

Br J Clin Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.
Tycho Heimbach, Yuan Chen, Jun Chen, Vaishali Dixit, Neil Parrott, Guoying Tai

Clin Pharmacol Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Gepotidacin in Renal Impairment.
Mohammad Hossain, Courtney Tiffany, Aparna Raychaudhuri, Dung Nguyen, Guoying Tai

Clin Pharmacol Drug Dev· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.
Emile P Chen, Guoying Tai, Harma Ellens

Pharm Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of physiologically based pharmacokinetic modeling and simulation in drug development.
Carole E Shardlow, Grant T Generaux, Aarti H Patel, Guoying Tai, Thuy Tran

Drug Metab Dispos· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mechanism-based mathematical model of aryl hydrocarbon receptor-mediated CYP1A induction in rats using beta-naphthoflavone as a tool compound.
Emile P Chen, Liangfu Chen, Yan Ji, Guoying Tai, Yuan H Wen

Drug Metab Dispos· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry.
Carrie M Mosher, Guoying Tai, Allan E Rettie

J Pharmacol Exp Ther· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-engineering of CYP2C9 to probe acid-base substrate selectivity.
Guoying Tai, Leslie J Dickmann, Nicholas Matovic, James J DeVoss, Elizabeth M J Gillam

Drug Metab Dispos· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmocogenomics of warfarin: closing in on personalized medicine.
Allan E Rettie, Guoying Tai

Mol Interv· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
Guoying Tai, Frederico Farin, Mark J Rieder, Albert W Dreisbach, David L Veenstra

Pharmacogenet Genomics· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians.
Allan E Rettie, Guoying Tai, David L Veenstra, Fred M Farin, Sengkeo Srinouanprachan

Blood· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis